Cell Therapy for Parkinson’s Disease at Plexus

A  Different Approach to Parkinson’s Disease

 

Every existing pharmacological treatment for Parkinson’s disease works downstream of the disease process. Levodopa replaces dopamine that the brain is no longer producing adequately. Dopamine agonists mimic its action. MAO-B inhibitors slow its breakdown. Each of these approaches manages the consequence of dopaminergic neurodegeneration. None of them addresses the degeneration itself.

Cell therapy for Parkinson’s disease works differently. It engages directly with the neurobiological source of the condition, targeting the environment in which surviving dopaminergic neurons exist and working to protect them from the degeneration that is driving the condition forward.

At plexus, cell therapy for Parkinson’s is delivered as the biological core of a Regenerative Rehabilitation Programme, not as a standalone intervention. Founded by Dr. Na’eem Sadiq with over 35 years of neurological expertise and more than 500,000 patients treated, plexus is India’s first ISO-certified regenerative rehabilitation and research centre. It is the most clinically credible destination in India for Parkinson’s disease cell therapy, bringing together the neurobiological intervention, the specialist team, the rehabilitation infrastructure, and the ISO-certified quality standards that this level of treatment demands.

What Is Cell Therapy for Parkinson’s Disease 

Cell therapy for Parkinson’s disease at plexus uses autologous mesenchymal cell therapy. The term autologous means the cells are drawn from the patient’s own body, specifically from bone marrow, eliminating the immune compatibility concerns that arise with donor-sourced cell approaches.

The process involves three steps:

• Harvest: Mesenchymal cells are aspirated from the patient’s bone marrow under local anaesthesia. No general anaesthesia is required. The procedure is minimally invasive and does not require open surgery or extended hospitalisation.

• Processing: The harvested cells are prepared under plexus’s ISO-certified laboratory conditions. Every stage of laboratory processing, from centrifugation and isolation through to quality verification, is conducted under independently certified protocols that verify cell viability and safety before administration.

• Administration: The processed cells are administered into the central nervous system. The delivery route and timing are determined by the treating neurologist based on the patient’s clinical profile and assessment findings.

Because the cells are the patient’s own, there is no risk of immune rejection, no requirement for immunosuppressive medication, and no donor dependency or matching process.

How Does Advanced Cell Therapy for Parkinson’s Disease Work Neurologically?

Advanced cell therapy Parkinson’s  targets the condition through four neurobiological mechanisms that pharmacological therapy cannot replicate:

Neuroprotection of Surviving Dopaminergic Neurons

• The primary target of cell therapy for Parkinson’s disease is the surviving population of dopaminergic neurons in the substantia nigra pars compacta. As Parkinson’s disease progresses, the rate of neuronal loss determines the pace of motor symptom worsening and the declining window during which medication remains effective. Administered mesenchymal cells help protect these surviving neurons from further alpha-synuclein-driven degeneration, directly influencing the biological trajectory of the condition.

Neuroinflammation Modulation

• Chronic neuroinflammation is an established and clinically significant driver of neuronal loss in Parkinson’s disease. Activated microglia release pro-inflammatory cytokines that create a hostile neurological environment accelerating dopaminergic neuron death. This inflammatory burden continues regardless of how well motor symptoms are pharmacologically managed. Administered mesenchymal cells exert a regulatory effect on microglial activation, shifting the neuroinflammatory environment toward one that supports neuronal survival rather than driving further degeneration.

Neurotrophic Factor Secretion

• Mesenchymal cells secrete brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor, two well-characterised proteins with established roles in dopaminergic neuron survival, synaptic integrity maintenance, and functional connectivity across the motor and non-motor circuits disrupted by Parkinson’s disease. This trophic support provides a biological input to the Parkinson’s brain that no currently available pharmacological therapy delivers.

Multi-System Neurological Stabilisation

• Parkinson’s disease disrupts neurological systems well beyond the nigrostriatal pathway. Lewy body pathology spreads across the locus coeruleus, the dorsal raphe nucleus, the autonomic nervous system networks, and eventually the cortex, producing the non-motor symptom profile that medication cannot adequately address. The broader anti-inflammatory and neuroprotective action of mesenchymal cell therapy contributes to the stabilisation of these wider networks, supporting the autonomic, cognitive, and sleep-regulating systems alongside the motor circuitry.

What Does Regenerative Therapy for Parkinson’s at Plexus Involve?

Regenerative therapy for Parkinson’s at plexus is structured around three integrated clinical stages:

Comprehensive Assessment

Before any treatment begins, the plexus specialist team conducts a thorough multi-domain clinical evaluation:

• Motor symptom profiling including tremor, rigidity, bradykinesia, postural stability, and gait analysis
• Non-motor symptom review including autonomic function, sleep architecture, mood, olfactory status, and cognitive screening
• Full medication history and response review
• Functional independence assessment across daily activities, personal care, and mobility
• Fall risk profiling informing rehabilitation programme calibration

Autologous Mesenchymal Cell Therapy Procedure

• Cells are harvested under local anaesthesia, processed under ISO-certified conditions, and administered into the central nervous system, without open surgery, without general anaesthesia, and without extended hospitalisation.

Integrated Regenerative Rehabilitation Programme

Following cell therapy, patients begin a structured multidisciplinary programme incorporating:

• Physiotherapy for motor retraining, gait correction, balance, and rigidity management
• Occupational Therapy for daily independence, hand function, and home safety
• Aquatic Therapy for balance and postural strength at India’s first hospital-integrated aquatic therapy pool
• Speech Therapy and Swallowing Therapy where communication and nutritional safety are clinically affected
• Cognitive Rehabilitation where attentional function, memory, or executive skill is part of the clinical picture

How Does Cell Therapy for Parkinson’s Disease Compare to Other Treatment Options?

Factor	Levodopa and Pharmacological Therapy	Deep Brain Stimulation	Cell Therapy for Parkinson’s at plexus
Target	Downstream dopamine deficit	Motor circuit modulation	Neurodegeneration at biological source
Disease Modification	Not disease-modifying	Not disease-modifying	Aims to slow neurodegeneration
Non-Motor Symptoms	Not addressed	Not addressed	Broader neurological support
Invasiveness	Oral medication	Brain surgery with general anaesthesia	Minimally invasive, no open surgery
Immune Risk	Medication side effects	Surgical infection risk	No immune rejection with autologous cells
Rehabilitation Integration	Separate	Separate	Fully integrated within programme
ISO Certification	Not applicable	Not standard	ISO-certified at plexus

Who Should Consider Cell Therapy for Parkinson’s Disease ?

plexus’s clinical team assesses each patient individually. Cell therapy for Parkinson’s is most appropriate for patients who:

• Have a confirmed Parkinson’s disease diagnosis at any stage where motor symptoms, non-motor features, or both are meaningfully affecting function, independence, or quality of life.

• Are seeking advanced cell therapy Parkinson’s treatment that addresses the neurological source of the condition rather than only managing symptoms.

• Find that current pharmacological management provides incomplete or declining control.

• Are not planning to pursue surgical intervention or are not eligible for deep brain stimulation.

• Are medically stable and able to engage consistently with a structured multidisciplinary rehabilitation programme.

What Improvements Have Patients Experienced Through Cell Therapy for Parkinson’s at Plexus?

Patients who have completed cell therapy for Parkinson’s disease within plexus’s Regenerative Rehabilitation Programme have reported:

• Reduction in tremor amplitude and frequency, with greater hand steadiness sustained across daily activities.

• More fluid and spontaneous movement, with less effort required to initiate walking, rise from a chair, and navigate between positions.

• More stable gait pattern with improved stride length, reduced festination, and fewer freezing episodes.

• More consistent medication response, with pharmacological therapy functioning more effectively alongside the broader neurological improvement.

• Improved speech volume and clarity, supported through Speech Therapy integrated within the programme.

• Improved sleep quality and reduction in REM sleep behaviour disorder episodes.

• Greater cognitive consistency and attentional steadiness where cognitive symptoms are part of the clinical picture.

Why Plexus Is India’s Most Credentialled Centre for Cell Therapy for Parkinson’s

India’s First ISO-Certified Regenerative Rehabilitation and Research Centre

• ISO certification at plexus covers the complete cell therapy process, from bone marrow aspiration and laboratory preparation through to central nervous system administration and post-treatment monitoring, providing independently verified quality assurance for every patient.

Advanced Cell Therapy Parkinson’s Within a Fully Integrated Programme

• Physiotherapy, Occupational Therapy, Aquatic Therapy, Speech Therapy, Swallowing Therapy, and Cognitive Rehabilitation are each designed to build directly on the neurological improvements initiated by cell therapy, within a single coordinated programme.

India’s First Hospital-Based Aquatic Therapy Pool

• plexus’s hospital-integrated Aquatic Therapy pool provides a unique rehabilitation resource for Parkinson’s patients with postural instability or fall risk, complementing the neurological improvements initiated by cell therapy.

Over 70 National and International Awards for Clinical Excellence

• More than 70 awards for clinical excellence in neurological and regenerative rehabilitation reflect consistent outcomes at plexus for patients with Parkinson’s disease across all stages and presentations.

Other Neurological Conditions Treated at plexus

Specialist programmes are available for Multiple Sclerosis, Spinocerebellar Ataxia, Motor Neuron Disease, Spinal Cord Injury, Stroke, Cerebral Palsy, Brachial Plexus Injury, Autoimmune Neurological Conditions, and Sports Injuries.

Source Transparency and Editorial Accountability

Supporting Evidence

• Barker, R.A., et al. (2017). New approaches to cell therapy for Parkinson’s disease. Nature Reviews Neurology, 13(11), 655-669. https://www.nature.com (Source for autologous mesenchymal cell therapy mechanisms, BDNF and GDNF secretion, neuroprotective action, and safety profile in Parkinson’s disease.)

• Bloem, B.R., Okun, M.S., Klein, C. (2021). Parkinson’s disease. The Lancet, 397(10291), 2284-2303. https://www.thelancet.com (Source for pharmacological treatment limitations, neurodegeneration mechanisms, and treatment landscape in Parkinson’s disease.)

• Hirsch, E.C., Vyas, S., Hunot, S. (2012). Neuroinflammation in Parkinson’s disease. Parkinsonism and Related Disorders, 18(S1), S210-S212.
   
• https://www.sciencedirect.com (Source for chronic neuroinflammation mechanisms, microglial overactivation, and accelerated neuronal loss in Parkinson’s disease.)

• Poewe, W., et al. (2017). Parkinson’s disease. Nature Reviews Disease Primers, 3, 17013. https://www.nature.com (Source for alpha-synuclein pathology, Lewy body spread, multi-system neurodegeneration, and non-motor symptom profiles in Parkinson’s disease.)

• Indian Council of Medical Research (ICMR). Guidelines on Regenerative Medicine and Cell-Based Therapies. https://www.icmr.gov.in
• ClinicalTrials.gov. Active and completed trials for cell-based therapies in neurodegenerative disorders. https://clinicaltrials.gov
• plexus Clinical Programme Data, used for editorial validation. plexus 

Revision Timeline: April 2026. Page first published covering cell therapy for Parkinson’s disease, autologous mesenchymal cell therapy mechanisms, Parkinson’s cell therapy side effects, regenerative therapy for Parkinson’s, and plexus’s Regenerative Rehabilitation Programme at Bangalore and Hyderabad centres.

Last Updated: April 2026

Frequently Asked Questions

Is cell therapy for Parkinson’s disease available at both plexus centres?

Yes. Cell therapy for Parkinson’s disease is available at plexus’s HRBR Layout and Kalyan Nagar centres in Bangalore, and at the Banjara Hills centre in Hyderabad, open Monday to Saturday from 8:30 AM to 6:30 PM. Consultations can be booked at plexus.

Is advanced cell therapy Parkinson’s at plexus a surgical procedure?

No. Advanced cell therapy Parkinson’s at plexus is minimally invasive. Cells are harvested under local anaesthesia, processed in an ISO-certified laboratory, and administered without open surgery or general anaesthesia. No extended hospitalisation is required.

Can cell therapy for Parkinson’s disease at plexus be combined with existing medication?

Yes. Cell therapy for Parkinson’s disease at plexus is designed to work alongside existing pharmacological management. No medication changes are made without the direct involvement of the patient’s own treating neurologist.

How long does cell therapy for Parkinson’s at plexus take to show results?

Improvements through cell therapy for Parkinson’s at plexus develop progressively over weeks to months and are reinforced through the integrated Regenerative Rehabilitation Programme. The timeline is individualised based on each patient’s disease stage, symptom profile, and rehabilitation response, and is reviewed regularly throughout the programme.

Is regenerative therapy for Parkinson’s at plexus suitable for patients at all stages of the condition?

Yes. Regenerative therapy for Parkinson’s at plexus is clinically relevant from the early stages, when neuroprotective potential is greatest, through to advanced presentations where neurological stabilisation and quality of life preservation are the primary goals. Every programme is individualised following a comprehensive multi-domain assessment.